The key evidence distinction
Thymosin beta-4 has an early clinical footprint in wound research. The fragment sold as TB-500 has a much thinner direct human evidence base, so parent-protein study protocols cannot be treated as a validated fragment schedule.
What remains unknown
- Human pharmacokinetics for common research-vendor formulations.
- Dose response for the fragment's marketed recovery claims.
- Long-term safety and validated monitoring.
What this evidence review covers
Explain why full-length thymosin beta-4 studies cannot establish a TB-500 fragment schedule.
- Entity mismatch before any study table
- Full-length phase 1 exposure as historical context only
- Route/formulation mismatch
- No injury cycle or daily protocol
- No animal-to-human conversion
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
entity mismatch
Full-length Tβ4 doses in a phase 1 study are not TB-500 fragment doses.
regulatory
FDA found no human exposure data for the TB-500 fragment.
| Evidence class | What the source supports |
|---|---|
| entity mismatch | Full-length Tβ4 doses in a phase 1 study are not TB-500 fragment doses. |
| regulatory | FDA found no human exposure data for the TB-500 fragment. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Intravenous full-length thymosin beta-4 in healthy volunteers
Evidence class: primary randomized phase 1 entity mismatch. What it supports: Short-term tolerability and pharmacokinetics of characterized full-length thymosin beta-4 in healthy volunteers.
What it does not establish: TB-500 fragment identity, TB-500 safety, injury healing, retail-product quality, or a TB-500 dose.
FDA bulk substances that may present significant safety risks
Evidence class: primary regulatory. What it supports: FDA's BPC-157, injectable GHK-Cu, and TB-500 fragment safety/characterization statements; no identified human TB-500 fragment exposure data.
What it does not establish: A diagnosis, individual risk estimate, or claim that topical GHK-Cu and injectable GHK-Cu share one risk profile.
Questions this page answers
What is the standard TB-500 cycle?
No validated human fragment schedule was identified.
Can I use the thymosin beta-4 trial dose?
No. It studied a different entity under a controlled protocol.
What remains unresolved
- No human dose-ranging fragment study.
- No injury-efficacy trial for the fragment.
- No stack evidence with BPC-157.